SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic agents that have been reported to improve non-alcoholic fatty liver disease (NAFLD) and reduce aspartate transaminase levels and hepatic steatosis in patients with NAFLD and type 2 diabetes mellitus (T2DM) [17,18].